Visible Genetics Inc.(VGIN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Visible Genetics Inc.(VGIN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (169)	3/19/1998 9:42:00 AM
From: Biomaven	Read Replies (1) of 337

Richard, I think the key questions are whether HIV genotyping of patients a) improves clinical outcomes and b) reduces overall cost of treatment. Seems to me that answering those two questions is a _major_ research project that I doubt if VGINF and CPI can fund and perform alone. I also doubt that any of the individual drug companies (Roche, Merck, Glaxo, Agouron etc.) would want to fund this research, as they might not like the answers it produces. Maybe VGINF should apply for NIH money. The question then becomes does VGINF have a viable product in this area until the above questions have been answered in the affirmative? Why do you see the Abbot purchase of Murex as good news for VGINF? The Murex/Digene stuff is at least partly competitive with VGINF. I don't really see VGINF as an acquisition candidate by one of the big pharms involved with HIV, as they can't be sure it will help them push their particular drug. BTW, I hope VGINF knows to knock on Sepracor's door - they just announced a new project (with ARQL) to develop PI's specifically for resistant HIV strains. I still have a very small holding in VGINF left, currently not sure whether I should get back in again. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next